Mark J. Foley Sells 10,000 Shares of Zeltiq Aesthetics Inc. (ZLTQ) Stock
Zeltiq Aesthetics Inc. (NASDAQ:ZLTQ) insider Mark J. Foley sold 10,000 shares of the stock in a transaction that occurred on Monday, November 14th. The stock was sold at an average price of $39.54, for a total transaction of $395,400.00. Following the sale, the insider now owns 261,941 shares in the company, valued at approximately $10,357,147.14. The transaction was disclosed in a document filed with the SEC, which is available at this link.
Zeltiq Aesthetics Inc. (NASDAQ:ZLTQ) opened at 40.86 on Thursday. The company has a 50-day moving average of $37.71 and a 200 day moving average of $33.62. Zeltiq Aesthetics Inc. has a 12-month low of $18.41 and a 12-month high of $41.48. The firm has a market cap of $1.63 billion, a price-to-earnings ratio of 52.72 and a beta of 0.89.
Zeltiq Aesthetics (NASDAQ:ZLTQ) last posted its earnings results on Wednesday, November 9th. The company reported $0.12 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.08 by $0.04. Zeltiq Aesthetics had a net margin of 9.48% and a negative return on equity of 6.45%. The business had revenue of $95.20 million for the quarter, compared to analysts’ expectations of $90.84 million. During the same period in the prior year, the company posted $0.05 EPS. The business’s revenue for the quarter was up 55.6% compared to the same quarter last year. Equities analysts expect that Zeltiq Aesthetics Inc. will post ($0.08) EPS for the current fiscal year.
A number of brokerages have weighed in on ZLTQ. Zacks Investment Research lowered shares of Zeltiq Aesthetics from a “strong-buy” rating to a “hold” rating in a research report on Saturday, November 12th. Northcoast Research restated a “buy” rating on shares of Zeltiq Aesthetics in a research report on Tuesday, November 8th. Canaccord Genuity raised their target price on shares of Zeltiq Aesthetics from $41.00 to $45.00 and gave the company a “buy” rating in a research report on Thursday, November 10th. Brean Capital restated a “buy” rating on shares of Zeltiq Aesthetics in a research report on Monday, October 24th. Finally, Stifel Nicolaus raised their target price on shares of Zeltiq Aesthetics from $38.00 to $52.00 and gave the company a “buy” rating in a research report on Wednesday, September 21st. Three investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $42.78.
A number of hedge funds have recently bought and sold shares of the company. PineBridge Investments L.P. boosted its stake in Zeltiq Aesthetics by 4.9% in the second quarter. PineBridge Investments L.P. now owns 4,103 shares of the company’s stock valued at $112,000 after buying an additional 193 shares in the last quarter. BlackRock Inc. boosted its stake in Zeltiq Aesthetics by 11.3% in the third quarter. BlackRock Inc. now owns 3,265 shares of the company’s stock valued at $128,000 after buying an additional 332 shares during the period. Teacher Retirement System of Texas boosted its stake in Zeltiq Aesthetics by 26.9% in the second quarter. Teacher Retirement System of Texas now owns 4,884 shares of the company’s stock valued at $133,000 after buying an additional 1,036 shares during the period. Mason Street Advisors LLC bought a new stake in Zeltiq Aesthetics during the second quarter valued at $173,000. Finally, Bank of Montreal Can boosted its stake in Zeltiq Aesthetics by 49.2% in the third quarter. Bank of Montreal Can now owns 4,794 shares of the company’s stock valued at $188,000 after buying an additional 1,580 shares during the period.
About Zeltiq Aesthetics
ZELTIQ Aesthetics, Inc is a medical technology company. The Company focuses on developing and commercializing products utilizing its controlled-cooling technology platform. Its product, the CoolSculpting System, is designed to reduce stubborn fat bulges. It sell the CoolSculpting system primarily to dermatologists, plastic surgeons, aesthetic specialists, and obstetrics and gynecology physicians.
Receive News & Stock Ratings for Zeltiq Aesthetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zeltiq Aesthetics Inc. and related stocks with our FREE daily email newsletter.